News
BADBIR Team at the July 2022 BAD Annual Meeting
The BADBIR team will be present in Glasgow for the 2022 BAD Annual Meeting 5th - 7th July.We will have a stand in the exhibition hall plus presentations in the morning Medical Dermatology session (Effect modification of biologic survival by patient characteristics)...
Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models
Scientific Reports, 2021.Jalali-Najafabadi F, Stadler M, Dand N, Jadon D, Soomro M, Ho P, Marzo-Ortega H, Helliwell P, Korendowych E, Simpson MA, Packham J, Smith CH, Barker JN, McHugh N, Warren RB, Barton A, Bowes J; BADBIR Study Group; BSTOP Study Group.Read...
Defining Trajectories of Response in Psoriasis Patients Treated with Biologic Therapies
Br J Dermatol, 2021.Geifman N, Azadbakht N, Zeng J, Wilkinson T, Dand N, Buchan I, Stocken D, Di Meglio P, Warren RB, Barker JN; Reynolds NJ, Barnes MR, Smith CH, Griffiths CEM, Peek N; BADBIR Study Group, on behalf of the PSORT Consortium.Read publication: Br J...
Ethics Progress Report: 2021
Read the 2021 Ethics Progress Report. Related Contact Us Tel: +44 (0)161 306 1896 Email: badbir@manchester.ac.uk Find Us The University of ManchesterFirst Floor Bright BuildingManchester Science ParkManchesterM15 6GZ Connect With...
Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs nonâ€biologic systemic therapies
JEADV, 2021.Mason KJ, Burden AD, Barker J, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ, Ormerod ADRead publication: JEADV 2021 Related Contact Us Tel: +44 (0)161 306 1896 Email:...
Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR
JEADV, 2021.Mason KJ, Burden AD, Barker J, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ; Ormerod AD; BADBIR Study Group.Read publication: JEADV 2021 Related Contact Us Tel: +44 (0)161 306 1896 Email:...
Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register
JAMA Dermatol, 2020.Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group.Read publication: JAMA Dermatol Related Contact Us Tel: +44 (0)161 306 1896 Email: badbir@manchester.ac.uk Find...
The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology
Br J Dermatol, 2020.Yiu ZZN, Mason KJ, Smith CH, Griffiths CEM; BADBIR Study Group.Read publication: Br J Dermatol Related Contact Us Tel: +44 (0)161 306 1896 Email: badbir@manchester.ac.uk Find Us The University of ManchesterFirst Floor...
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Br J Dermatol, 2020.Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group.Read publication: Br J Dermatol Related Contact Us Tel: +44 (0)161 306 1896 Email: badbir@manchester.ac.uk Find...
Amendment 12
Study Amendment 12 to BADBIR has implementation date of 06/10/2020. Documents in this amendment You can download all of the files for this amendment in one go using the link below (.zip file). If you would like the tracked changes versions of the documents to see...
Contact Us
Find Us
The University of Manchester
First Floor Bright Building
Manchester Science Park
Manchester
M15 6GZ
